Analysts Set Gain Therapeutics, Inc. (NASDAQ:GANX) Target Price at $8.50

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have been assigned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $7.50.

Several research firms recently commented on GANX. BTIG Research reiterated a “buy” rating and issued a $5.00 price target on shares of Gain Therapeutics in a research report on Tuesday. Roth Mkm reaffirmed a “buy” rating on shares of Gain Therapeutics in a research note on Tuesday, May 12th. Oppenheimer reaffirmed an “outperform” rating on shares of Gain Therapeutics in a research report on Wednesday, May 27th. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a research note on Wednesday. Finally, Wall Street Zen upgraded Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, June 21st.

Gain Therapeutics Stock Performance

Shares of NASDAQ:GANX opened at $1.91 on Friday. Gain Therapeutics has a 52 week low of $1.41 and a 52 week high of $4.34. The stock has a market capitalization of $81.47 million, a P/E ratio of -3.29 and a beta of 0.15. The firm has a fifty day simple moving average of $1.82 and a two-hundred day simple moving average of $2.12. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.02.

Gain Therapeutics (NASDAQ:GANX) last posted its earnings results on Monday, May 11th. The company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13). During the same quarter in the prior year, the company earned ($0.16) earnings per share. On average, analysts expect that Gain Therapeutics will post -0.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Gain Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its position in shares of Gain Therapeutics by 2.9% during the second quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock worth $523,000 after acquiring an additional 8,251 shares during the period. Marshall Wace LLP boosted its holdings in shares of Gain Therapeutics by 41.0% in the second quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock valued at $498,000 after purchasing an additional 80,407 shares during the period. JPMorgan Chase & Co. bought a new position in Gain Therapeutics in the third quarter worth approximately $47,000. Squarepoint Ops LLC bought a new position in Gain Therapeutics in the third quarter worth approximately $68,000. Finally, Virtu Financial LLC increased its holdings in Gain Therapeutics by 126.9% during the 3rd quarter. Virtu Financial LLC now owns 54,008 shares of the company’s stock worth $96,000 after purchasing an additional 30,207 shares during the period. 11.97% of the stock is currently owned by institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.